Brca variants do not increase the risk of adverse reactions in patients with ovarian cancer: a single-center real-world study

HIGHLIGHTS

  • who: Kemin Li from the University of Miami, United States have published the research work: BRCA Variants Do Not Increase the Risk of Adverse Reactions in Patients With Ovarian Cancer: A Single-Center Real-World Study, in the Journal: (JOURNAL)
  • what: The results of the study demonstrate that the occurrence of carboplatin allergic reactions during chemotherapy in ovarian cancer patients with pathogenic BRCA variants was substantially increased; however, the multivariate COX analysis did not show statistical significance. Using realworld data, this study shows that the occurrence of myelosuppression (including leukopenia, neutropenia, Frontiers in Oncology | www . . .

     

    Logo ScioWire Beta black

    If you want to have access to all the content you need to log in!

    Thanks :)

    If you don't have an account, you can create one here.

     

Scroll to Top

Add A Knowledge Base Question !

+ = Verify Human or Spambot ?